Analyst Price Target is $6.00
▲ +265.85% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Adaptimmune Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $10.00 and a low forecast of $3.00. The average price target represents a 265.85% upside from the last price of $1.64.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Adaptimmune Therapeutics. This rating has held steady since December 2022, when it changed from a Hold consensus rating.